Prosacea — Kobayashi Healthcare International, Inc. drug label update
Kobayashi Healthcare International, Inc. has updated the drug label for Prosacea, indicating use for the treatment of rosacea, redness, acne, and other skin eruptions.
This update affects Kobayashi Healthcare International, Inc. and personnel responsible for the labeling, regulatory compliance, and distribution of OTC rosacea and acne treatments.
The addition or refinement of specific indications such as 'redness' and 'other eruptions of the skin' suggests a requirement for precise alignment between marketing claims and the approved drug facts label. For regulatory professionals, this underscores the importance of maintaining consistent nomenclature across the product's therapeutic applications to ensure compliance with OTC monograph or approval requirements.
Regulatory teams should ensure that all therapeutic claims regarding redness and acne eruptions are fully supported by internal data and aligned with the updated label. Quality and labeling departments should confirm that current inventory and future production runs reflect this specific indication wording.
Prosacea (Kobayashi Healthcare International, Inc.). Uses For the treatment of rosacea, redness, acne and other eruptions of the skin.
Open in openFDA / FDA.gov